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Queensland, AustraliaABSTRACT Molecular dynamics simulations and free energy calculations have been used to examine in detail the mechanism
by which a receptor molecule (the glycopeptide antibiotic vancomycin) recognizes and binds to a target molecule (lipid II)
embedded within a membrane environment. The simulations show that the direct interaction of vancomycin with lipid II, as
opposed to initial binding to the membrane, leads most readily to the formation of a stable complex. The recognition of lipid II
by vancomycin occurred via the N-terminal amine group of vancomycin and the C-terminal carboxyl group of lipid II. Despite
lying at the membrane-water interface, the interaction of vancomycin with lipid II was found to be essentially identical to that
of soluble tripeptide analogs of lipid II (Ac-D-Ala-D-Ala; root mean-square deviation 0.11 nm). Free energy calculations also
suggest that the relative binding affinity of vancomycin for native, resistant, and synthetic forms of membrane-bound lipid II
was unaffected by the membrane environment. The effect of the dimerization of vancomycin on the binding of lipid II, the position
of lipid II within a biological membrane, and the effect of the isoamylene tail of lipid II on membrane fluidity have also been
examined.INTRODUCTIONVancomycin and related glycopeptide antibiotics block key
steps in the biosynthesis of the peptidoglycan component of
the cell wall in Gram-positive bacteria. Vancomycin is
known to act by binding to the C-terminal peptide of the
peptidoglycan precursor lipid II. Although vancomycin
once served as an antibiotic of last resort, the growing prev-
alence of vancomycin-resistant enterococci and vancomy-
cin-resistant Staphylococcus aureus has decreased its
utility (1,2). Vancomycin resistance in vancomycin-resistant
enterococci and vancomycin-resistant S. aureus is associ-
ated with the substitution of the terminal D-Ala-D-Ala by
D-Ala-D-Lac in lipid II. Crystallographic (3–7) and NMR
(8–13) studies of vancomycin and low-molecular-weight
di- and tripeptide analogs of lipid II suggest that the
C-terminus of the ligand binds within a pocket formed by
the first four residues of vancomycin. As illustrated in
Fig. 1, the backbone of the ligand lies antiparallel to the
backbone of vancomycin and the complex is stabilized by
a series of b-sheet-like backbone-backbone hydrogen
bonds. Although multiple structures of vancomycin bound
to different peptides have been solved experimentally, to
date, no structural data related to the binding of vancomycin
bound to lipid II in a physiologically relevant membrane
environment are available. Lipid II is insoluble in waterSubmitted August 22, 2011, and accepted for publication October 31, 2011.
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. Open access under CC BY-NC-ND license.and it has not been possible to isolate a vancomycin-lipid
II complex that is amenable for study by either x-ray crys-
tallography or NMR.
This raises the question of whether vancomycin binds to
membrane-bound lipid II in a similar manner to di- and
tripeptide analogs in solution. Another question is whether
other functional groups within lipid II, such as the n-acetyl-
muramic acid and n-acetylglucosamine sugar moieties, also
interact directly with vancomycin and help stabilize the
membrane-bound complex. In fact, the affinity of vancomy-
cin for membrane-bound lipid II has only been measured
directly for the native form of lipid II. No experimental
data on the affinity of vancomycin to resistant forms of lipid
II in a membrane environment are publicly available. Thus,
whereas binding is dominated by the terminal two residues
of lipid II (D-Ala-D-Ala) free in solution, the role played by
residues 3 and 4, L-Lys and g-D-Glu, respectively, in deter-
mining the interaction of vancomycin with membrane-
bound lipid II, is unknown. Because these residues form
different contacts in alternative crystal forms, this has led
to considerable debate in the literature concerning their
roles in vivo. Finally, like other proteins and peptides that
target specific lipids, vancomycin must recognize lipid II
efficiently. How this is achieved against the background of
other lipids, especially given the general complexity of the
bacterial plasma membrane, is not, as of this writing, well
understood for any system.
In this work, molecular dynamics simulations have been
used to examine the mechanism of recognition of native
vancomycin to membrane-bound lipid II. The aim was to
investigate basic questions related to how molecules such
as vancomycin recognize a given lipid in a membrane envi-
ronment. These included whether vancomycin binds to thedoi: 10.1016/j.bpj.2011.10.047
FIGURE 1 Interaction of vancomycin with the
lipid II analog Ac-D-Ala-D-Ala. Vancomycin resi-
dues are numbered 1–7 from the N-terminus.
(Red and gray) Vancosamine. (Dashed lines)
Specific hydrogen bonds believed to stabilize the
complex.
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interface, and whether the nature of the interaction between
vancomycin- and membrane-embedded lipid II is similar to
that observed for peptide analogs free in solution. In addi-
tion, free energy calculations have been used to estimate,
to our knowledge for the first time, the difference in rela-
tive-binding free energy of the interaction of vancomycin
with native, resistant, and synthetic forms of membrane-
bound lipid II. To validate these calculations, the interaction
of vancomycin with a range of soluble peptide analogs free
in solution was also examined and the results compared
directly with binding data obtained experimentally.METHODS
Molecular dynamics simulations
All simulations were performed under periodic conditions using the
GROMACS (Groningen Machine for Chemical Simulation) package Ver.
4.0.5 (14,15) in conjunction with the GROMOS 54A7 force field (16).
The solvent water was described using the simple point charge water model
(17). The solvent and solute were coupled independently to an external
temperature bath (298 K or 310 K depending on the system) with a coupling
constant of 0.1 ps using a Berendsen thermostat (18). Note that the simula-
tions in solution were performed at 298 K in order that a direct comparison
could be made between the simulations and the available experimental
binding data. The simulations of the membrane systems were performed
at 310 K to ensure that the 2-oleoyl-1-palmitoyl-sn-glycero-3-phosphocho-
line (POPC) remained in a liquid-crystalline phase. POPC was used to form
the membrane because most experimental studies of the interaction of van-
comycin with biological membranes, including its binding to membrane-
bound lipid II, have been performed using PC lipids. The pressure wasmaintained at 1 bar using a Berendsen barostat with a time constant of
4 ps with a compressibility of 4.0  105 bar1.
The LINCS algorithm (19) was used to constrain the length of all cova-
lent bonds within the solute and the SETTLE algorithm (20) was used to
constrain the geometry of the water molecules. The equations of motion
were integrated using the leapfrog scheme. The nonbonded interactions
were evaluated using a twin-range method. Interactions within the short-
range cutoff of 0.8 nm were calculated every step. Interactions within the
long-range cutoff of 1.4 nm were recalculated every three steps, together
with the pair list. To correct for the truncation of electrostatic interactions
beyond the long-range cutoff, a reaction-field correction was applied using
a value of 78 for the relative dielectric permittivity (21).
To further extend the timescale that could be simulated, the mass of
hydrogen atoms was increased to 4 amu by transferring mass from the
atom to which it was attached. This redistribution of mass dampens high-
frequency local motions allowing a time step of 4 fs to be used to integrate
the equations of motion. The potential energy function is unchanged and the
redistribution does not affect the thermodynamic properties of the system
(22). It should also be noted that the GROMOS 54A7 force field is
a united-atom force field in which only polar and aromatic hydrogen are
treated explicitly. Thus, this modification primarily affects the librational
motion of water. It has no effect on the hydrogen-rich lipid tails nor any
significant affect of the overall diffusion properties of the water, peptide,
or lipid. The initial structure of the vancomycin dimer with and without
ligand was taken from PDB entry 1FVM (3). The structure of lipid II
was constructed based on PDB entry 1WCO (23). The lipid II-POPC
membrane was constructed by replacing selected POPC molecules on
one side of a preequilibrated POPC membrane (24,25) with lipid II mole-
cules. The system was then re-solvated in a simulation box and a 10-ns
simulation was performed to equilibrate the system.
For the simulations of the spontaneous binding of vancomycin to
membrane-bound lipid II, a vancomycin dimer was placed in a random
orientation 2 nm above the surface of the preequilibrated lipid II-POPC
membrane described earlier. The distance between vancomycin and any
lipid II molecule was at least 1 nm. For the free energy calculations, oneBiophysical Journal 101(11) 2684–2692
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was truncated in the z axis and the lipid II molecules not involved in the
final complex were replaced by POPC molecules. For the calculations
involving vancomycin and the peptide ligands free in solution, the initial
conformation of the complex was taken from PDB entry 1FVM. In each
case, the system was first solvated in a box of simple point charge water
molecules and minimized for 500 steps using a steepest-descent algorithm.
To further relax the solvent, 50 ps of dynamics at 298 K was then performed
in which the positions of the heavy atoms of both vancomycin and the
ligand were harmonically restrained using a force constant of
1000 kJ.mol1.nm2. A summary of each system simulated is given in Table
S1 and Table S2 in the Supporting Material.Parameterization of vancomycin and lipid II
Vancomycin and lipid II contain a number of nonstandard amino acids. To
generate an appropriate molecular topology file for vancomycin, the Auto-
mated Topology Builder (ATB, http://compbio.biosci.uq.edu.au/atb/) (26)
was used to identify all bonds, bond angles, and dihedral angles. The interac-
tion parameters were then assigned by identifying similar atom, bond, angle,
and dihedral-angle types from amino acids within the GROMOS 54A7 force
field. Topology files in GROMOS and GROMACS formats are available for
download via the ATB. Note that two topologies for vancomycin were gener-
ated. In one, the vancosaminewas protonated. In the other, vancosaminewas
deprotonated to investigate the effect of pH on ligand binding (27,28).Free energy calculations
The difference in Gibbs energy (DG) associated with the binding of alter-
native forms of lipid II in a membrane environment or isolated peptide
C-terminal analogs of lipid II to vancomycin were obtained using the
coupling-parameter approach. The Hamiltonian of the system, H, was
expressed as a function of a coupling parameter, l, which describes the
path taken from the initial state (l ¼ 0) to the final state (l ¼ 1). DG was
then estimated using the thermodynamic-integration equation,
DG0/1 ¼
Zl¼ 1
l¼ 0

vHðlÞ
vl

l
dl;
where h.il denotes an ensemble average at a given value of l. The relative
free enthalpy of binding DDG was determined from the difference between
the value obtained when performing the same mutation free in solution and
when bound to the vancomycin or the same mutation in the membrane-
bound lipid II and membrane-bound lipid II interacting with vancomycin.
To prevent numerical instabilities as atoms were created or destroyed, the
soft-core potential as described by Beutler et al. (29) and Zacharias et al.
(30) was used. The thermodynamic-integration equation was integrated
by performing separate simulations at a series of 21 (0.0, 0.05, 0.1, .,
0.9, 0.95, and 1.0) l-points in both the bound and unbound states. Where
necessary, additional points at 0.02, 0.04, 0.06, 0.08, 0.92, 0.94, 0.96, and
0.98 were included to obtain a smooth integrand. For each l-point, the
system was first equilibrated 1 ns, and the derivative hvH/vlil was then
averaged over 4 ns in the case of simulations in solution and over 9 ns in
the case of simulations in the membrane.
In cases where the value of hvH/vlil had not converged, the simulations
were extended to 10–15 ns. The error in hvH/vlil was estimated using
a block-averaging procedure (31,32). The individual errors were integrated
from l ¼ 0 to l ¼ 1 to yield the estimate of the total error in DG given. To
determine the degree of convergence, thermodynamic cycles were con-
structed wherein the molecules were transformed from one to another in
a circular path. The degree of convergence was also checked by performing
the forward and reverse mutations. The error in the relative free energy,Biophysical Journal 101(11) 2684–2692DDG, obtained by taking the difference in free energy between two alterna-
tive ligands, was calculated as [(s1)2þ(s2)2]1/2, where s1 and s2 are the stan-
dard errors for the two different ligands, respectively. Before the relative
Gibbs energy was calculated, the values obtained for the forward and
reverse mutations were averaged. The standard error in this average was
calculated as [((s1)2þ(s2)2)/2]1/2.RESULTS AND DISCUSSION
Mechanism of binding
There is considerable uncertainty in relation to the mecha-
nism of binding of vancomycin to membrane-bound lipid
II. It has been shown, for example, that vancomycin has
a weak affinity for phospholipid membranes including those
consisting of pure PC lipids. It is possible, therefore, that
vancomycin initially binds directly to the membrane and
then diffuses in the plane of the membrane until it encoun-
ters a molecule of lipid II. Such a two-dimensional diffusion
mechanism is often proposed to facilitate binding to mole-
cules with low copy numbers on the surface of a cell.
However, the fact that the presence of even 0.1 mol % of
lipid II more than doubles the rate of association with the
membrane itself suggests that vancomycin may interact
directly with lipid II (33).
To examine the mechanism of binding of vancomycin to
membrane-bound lipid II, a series of 11 simulations, each
60 ns in duration, was performed. A vancomycin dimer
was placed in solution, 2 nm above a POPC membrane con-
taining three lipid II molecules. At physiological pH, the
protonation state of the amine group of vancosamine in
membrane-proximal vancomycin is uncertain. For this
reason, five simulations were performed with the amine
group protonated and six with the amine group deprotonated
(see Table S1). In all 11 simulations, the vancomycin spon-
taneously migrated to the surface of the membrane within
8 ns. In five of the 11 cases, the vancomycin interacted
directly with lipid II; in five cases, vancomycin bound
initially to the membrane; and in one case, vancomycin
bound to the membrane and lipid II almost simultaneously.
In those cases where vancomycin interacted with the
membrane directly, the binding to the interface appeared
superficial, with the vancomycin molecule adopting a range
of orientations. In three of the five cases in which vancomy-
cin bound directly to the membrane, an interaction with at
least one molecule of lipid II had formed within 50 ns.
In two of the 11 simulations, both in which vancomycin
had bound directly to lipid II, a stable complex between van-
comycin and lipid II formed within 60 ns. In both of these
cases, one involving protonated vancosamine and one in-
volving deprotonated vancosamine, the C-terminal D-Ala-
D-Ala group of lipid II bound to vancomycin in a mode
essentially identical to that observed in the crystal structure
of the vancomycin Ac-D-Ala-D-Ala complex (heavy atom
root mean-squared deviation (RMSD) ~0.1 nm). To examine
whether the other systems, including cases where
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ultimately converge to the same structure, two other simula-
tions (one involving protonated vancosamine and one
involving deprotonated vancosamine) were extended to
200 ns.
In both cases, the crystallographic binding mode was
adopted (after 100 ns and 175 ns, respectively). Once the
crystallographic binding mode was adopted, the complex
did not dissociate. Fig. 2 shows a plot of the RMSD with
respect to the x-ray structure of vancomycin bound to
Ac-D-Ala-D-Ala (CCDC 704975) (7) as a function of
time for two illustrative cases. The rapid drop in RMSD
corresponds to the initial interaction of vancomycin with
lipid II. A critical step in the formation the final complex
is the interaction between the positively charged
N-terminus of vancomycin and the negatively charged
C-terminus of lipid II (Fig. 2, dashed arrow). The impor-
tance of this interaction, which is illustrated in Fig. 3 B,
is supported experimentally. Vancomycin loses affinity
for lipid II analogs below pH 3 and above pH 8, close to
the pKa of the carboxyl group of the terminal D-Ala
(pKa ¼ 2.3) and the terminal amine of vancomycin
(pKa ¼ 8.9), respectively (27,28). Chemical modification
(neutralization) of the terminal amine of vancomycin also
leads to decreased binding affinity (13,34–36). Although
the interaction between the N-terminus of vancomycin
and the C-terminus of lipid II was required to form the final
complex, the rate-limiting step is the formation of the
backbone-backbone hydrogen bond between the carbonyl
group of residue 4 (p-(2-[a-4-L-epi-vancosaminyl]-b-1-D-
glucosyl)- D-phenylglycine) of vancomycin and the amide
group of the terminal D-Ala of lipid II (Fig. 2, solid arrow,
2). Note that this amide group is not present in the most
common vancomycin resistance form of lipid II where
the terminal D-Ala is mutated to D-Lac.FIGURE 2 Root mean-squared positional deviation of all heavy atoms of
the vancomycin-lipid II complex with respect to the crystal structures
(CCDC 704975) for systems 3 (solid) and 5 (shaded) (see Table S1 in
the Supporting Material). (Arrows) Critical steps in formation of the vanco-
mycin-lipid II complex. (Solid circle) Initial interaction between the
N-terminus of vancomycin and the C-terminus of lipid II; (solid triangle)
formation of the critical backbone-backbone hydrogen bond between van-
comycin and the terminal D-Ala of lipid II.In two of the five cases in which vancomycin bound
directly to the membrane, no interaction with lipid II was
observed within 60 ns despite the small size of the simula-
tion box. This suggests that the diffusion of vancomycin
in the plane of the membrane is slow compared to the direct
interaction of vancomycin with lipid II. Note that these
simulation studies and the experimental studies to which
they are compared were performed using lipids with phos-
phatidylcholine headgroups. Bacterial membranes, in
contrast, contain predominantly phosphatidylethanolamine
lipids and negatively charged lipids such as cardiolipin
and lipid with phosphatidylglycerol headgroups. The pres-
ence of negatively charged lipids could, in principle, affect
both the affinity of vancomycin for the membrane and the
ability of vancomycin to diffuse along the surface of the
membrane. However, because vancomycin is expected to
have a net charge of zero, or at most þ1e, around neutral
pH, the effect of the net charge on the lipid headgroup is
expected to be small.Role of dimerization
The activity of vancomycin derivatives, and members of the
glycopeptides antibiotic family in general, is correlated with
their propensity to dimerize (9,37). This has led some to
suggest that in vivo vancomycin binds two lipid II molecules
(38). There is, however, little direct evidence to support this
assertion. To test whether a single vancomycin dimer can
bind two lipid II molecules when both are bound to the
surface of a membrane, a series of six simulations were per-
formed in which two vancomycin dimers were placed in
solution 2 nm above a POPC membrane containing six
copies of lipid II. In one case, the vancomycin dimer bound
spontaneously to two lipid II molecules (one after 14 ns and
the second after 24 ns). This demonstrates that the sponta-
neous binding of a vancomycin dimer to two lipid II
molecules is possible, and would lead to the formation of
a stable pseudosymmetric dimeric complex. A major chal-
lenge in this work is that the precise physiological concen-
tration of lipid II in the region of peptaglycan synthesis is
unknown.
In a number of Gram-positive bacteria in which the
concentration of lipid II has been investigated (e.g., Liste-
ria monocytogenes, Micrococcus flavus, and Micrococcus
lysodeikticus), there are ~2  105 lipid II molecules per
cell. This leads to a ratio of lipid II/all phospholipids in
the cytoplasmic membrane of 1:108–1:190 (39). However,
from fluorescence studies, it is known that lipid II strongly
accumulates along the septum of the bacteria in regions of
active peptaglycan synthesis (40). Thus, the physiologi-
cally relevant will be much higher than the average. The
concentration of lipid II used in the simulations (lipid II/
POPC ¼ 6:122) was between 5- and 10-times higher
than the average concentration measured experimentally
to account for the effect of the accumulation of lipid IIBiophysical Journal 101(11) 2684–2692
FIGURE 3 Snapshots for the trajectory indi-
cating the mode of interaction between vancomy-
cin and membrane-bound lipid II. (A) The initial
configuration in which vancomycin is placed
above the membrane free in solution. (B) The
initial point of contact with the N-terminus of van-
comycin interacting with the C-terminus of lipid II.
(C) The final complex in which a vancomycin
dimer is bound to two lipid II molecules. (The
two vancomycin molecules in the dimer are in
yellow and silver, respectively.) The N-termini
are represented as a van der Waals spheres
(purple). The terminal Lys-D-Ala-D-Ala peptide
of lipid II is represented as a van der Waals surface
and colored according to atom type (C, cyan; N,
blue; O, red; H, white). The lipid II C55 tail
(blue), the disaccharide group (green), and residues
other than the tripeptide terminus (light cyan). The
POPC molecules are colored according to atom
type and have been made partially transparent to
improve clarity. (D) A superposition of the two
vancomycin monomers from the vancomycin lipid
II complex showing the interaction of four terminal
residues of lipid II. (Yellow and green) Individual
vancomycin molecules. (Pale yellow and silver,
respectively) Terminal four residues. (Red dotted
lines) Hydrogen-bonding interactions between
vancomycin and lipid II. (Mesh) Solvent-acces-
sible surface of one of the vancomycin molecules
(silver).
2688 Jia et al.in regions of peptaglycan synthesis. The concentration used
in the simulations is, in turn, much lower than that
observed in some in vitro experiments in which localized
domains containing ratios as high as 1:1 lipid II/DOPC
have formed spontaneously (41). Nevertheless, as the rele-
vant physiological concentration is not known precisely,
care must be taken in interpreting the results. In particular,
the timescale on which the complexes were observed to
form in the simulations would not necessarily reflect those
in vivo.
Although only one example of a dimeric 2:2 complex was
simulated, it is clear that the lipid II molecules do not neces-
sarily bind in a symmetric manner. In Fig. 3 C, it can be seen
that whereas the N-terminus of one vancomycin projectsBiophysical Journal 101(11) 2684–2692toward the membrane, the other projects away from the
membrane. The fact that vancomycin does not adopt a pref-
erential orientation on the surface of the membrane is rele-
vant for the design of vancomycin derivatives in which
a membrane anchor (a biphenyl group or a lipid tail) is
incorporated in an attempt to enhance binding to the bacte-
rial membrane (37,42). Most notably, the disaccharide
group attached to residue 4 was observed to lie within the
membrane in some cases while being fully exposed in
others. The attachment of a membrane anchor to this disac-
charide group may help orient vancomycin such that the
ligand-binding pocket as well as the N-terminus of vanco-
mycin is exposed to the solution facilitating the binding of
lipid II.
Binding of Vancomycin to Lipid II 2689Free enthalpy of binding
The change in free enthalpy or Gibbs energy (DG) associated
with the binding of vancomycin to a series of alternative
forms of lipid II in a membrane environment and to isolated
peptide C-terminal analogs of lipid II have been determined.
These calculations were performed primarily to investigate
the effect of the membrane environment on the binding
of vancomycin to native and resistant forms of lipid II
for which no direct experimental measurements are avail-
able. The change in free enthalpy, associated with the
binding to vancomycin of six alternative C-terminal peptides
(see Fig. 4), for which experimental data in solution are
available, was determined to validate the calculations. Four
forms of lipid II were considered in a membrane environ-
ment. These included native lipid II and two naturally occur-
ring resistant phenotypes -D-Ala-D-Lac and -D-Ala-D-Ser.
The -D-Ala-2S-isobutyric acid was included in the series to
increase the number of comparisons with data in solution.
The relative free enthalpy was estimated using the thermo-
dynamic integration approach.
The degree of convergence was monitored in two ways:
all mutations were performed in both the forward and the
reverse directions. We also constructed a series of thermody-
namic cycles in each environment. The thermodynamic
cycles for the different mutations are shown in Fig. S1 in
the Supporting Material. Taking the average of the forward
and backward mutations for each mutation, all thermody-
namic cycles in solution converged to within 2.5 kJ/mol,
whereas on the membrane they converged to within
4.0 kJ/mol. In addition, the average difference of the forward
and reverse mutations was 0.5 kJ/mol in water, 1.3 kJ/mol
when bound to vancomycin in solution, 6.3 kJ/mol for
membrane-bound lipid II, and 1.3 kJ/mol for vancomycin
bound to membrane-bound lipid II—indicating that the
calculations are well converged. The relative binding free
enthalpies, together with the available experimental data,
are shown in Table 1. Note that the experimental binding
data in Table 1 are given in terms of the absolute free
enthalpies of binding and the difference in free enthalpy
with respect to native ligand containing -D-Ala-D-Ala. The
calculated values are given only with respect to the nativeFIGURE 4 Alternative C-terminal groups of lipid II.ligand. The difference between the calculated and experi-
mental values for the binding of vancomycin to the isolated
peptides is also given for comparison. Note as well that, as
far as we are aware, no comparable experimental data for
vancomycin binding to membrane-bound resistant forms of
lipid II are available publicly. We would also note that the
data that are available for native lipid II was obtained for lipid
II embedded in a DOPC membrane.
In line with experimental observations, the calculations
predict that, in solution, the order of affinity would be
D-Ala-D-Ala > D-Ala-D-Gly > D-Ala-D-Ser >D-Ala-2S-
isobutyric acid > D-Ala-D-Lac >> L-Ala-L-Ala. Except
for the case of D-Ala-D-Lac, all the predicted values are
within the uncertainty of both the experiment and the
calculations. In the case of D-Ala-D-Lac in solution, the
predicted binding affinity is ~6.8 kJ/mol higher than
the observed binding affinity. Note that the change in
free energy for the mutation D-Ala-D-Ala to Ala-D-Lac in
both water and when bound to vancomycin, was in excess
of 200 of kJ/mol, making it difficult to obtain fully
converged estimates of binding affinity in this case. As
noted above, experimental data are only available for the
binding of vancomycin to the native form of lipid II in
a membrane environment. The calculations suggest,
however, that the relative binding affinity of vancomycin
for the alternative forms of lipid II in a membrane environ-
ment are essentially identical to the corresponding peptide
analogs free in solution.The roles of Lys and g-D-Glu in binding
In solution, the interaction of vancomycin with peptide
analogs of lipid II is dominated by interactions involving
the C-terminal D-Ala-D-Ala. Nevertheless, the possible
role of the neighboring Lys and g-D-Glu residues in stabi-
lizing the final complex has been the subject of continuing
debate (43). In solution, the mutation of Lys to Ala or
Gly results in only a minor decrease in binding affinity
(1 kJ/mol and 3.8 kJ/mol, respectively) (44). Removing
the g-D-Glu also does not affect the binding affinity signif-
icantly (44,45). In line with this, NMR and x-ray crystallo-
graphic studies suggest that the side chain of Lys can adopt
a range of alternative conformations (3,11). In a membrane
environment, however, the extent to which the g-D-Glu and
Lys residues may interact with vancomycin will be largely
determined by the extent to which they are exposed to
solvent or buried within the more hydrophobic membrane-
water interface.
From Fig. 3 C, it can be seen that vancomycin can interact
with lipid II such that the N-terminus of vancomycin
projects away from the membrane (in which case, the side
chains of the lipid II Lys and g-D-Glu are buried within
the water-membrane interface), or with the N-terminus of
vancomycin projecting toward the membrane (in which
case, the side chains of the lipid II Lys and g-D-Glu are fullyBiophysical Journal 101(11) 2684–2692
TABLE 1 Relative free enthalpies for the binding of lipid II analogs with vancomycin (kJ/mol)
Terminal peptide
Experiment Calculated Difference
Solution* Membraney Solution* Membraney Solution
DGexpt DDGexpt
z DGexpt DDGexpt
z DDGcal
z DDGcal
z DDGexpt-DDGcal
-D-Ala-D-Ala 33.15 1.3x (13,44,46–50) 05 1.3x 37.25 0.9 (32) 05 0.9 0 0 05 1.3
-D-Ala-D-Lac 15.55 0.7x (13,46–50) 17.65 1.5x — — 10.85 3.5 14.85 6.4 6.85 3.8
-D-Ala-2S-isobutyric acid 26.15 0.1 (48) 7.0 5 1.3 — — 6.45 1.5 6.45 2.4 0.65 2.0
-D-Ala-D-Ser 27.65 0.8 (48) 5.5 5 1.6 — — 3.15 1.7 3.45 2.4 2.45 2.3
-D-Ala-Gly 29.25 0.1 (48) 3.9 5 1.3 — — 1.35 2.6 — 2.65 2.9
-L-Ala-L-Ala Not detected (44) >33 — — 30.45 6.1 — —
*Values in solution correspond to the binding of an isolated tripeptide to dimeric vancomycin (vancosamine deprotonated). The reference tripeptide was the
terminal three resides of native lipid II (Ac2-L-Lys-D-Ala-D-Ala). The peptides differed with respect to the final two amino acids (indicated in bold).
yValues in the membrane environment correspond to the binding of membrane-bound lipid II to dimeric vancomycin (vancosamine deprotonated). In this
case, native lipid II was used as a reference. The other forms of lipid II differed with respect to the final two amino acids.
zValues correspond to the difference in free energy with respect to the binding of the native form of lipid II or the equivalent peptide analog.
xValues reflect an average over different experimental estimates. All values are given as mean5 SE.
2690 Jia et al.exposed to solvent). Fig. 3 D shows a superposition of the
two vancomycin monomers from the 2:2 vancomycin/lipid
II complex after 20 ns of equilibration together with the
four terminal residues of lipid II. It is clear from Fig. 3 D
that, whereas the terminal D-Ala-D-Ala binds in an almost
identical manner, the side chains of both Lys and g-D-Glu
adopt very different orientations. In the specific configura-
tion shown there is a hydrogen bond formed between the
g-D-Glu and the 6-hydroxyl group of the vancomycin
glucose. However, these residues are highly dynamic and
do not form specific stable interactions with vancomycin
in any of the simulations.Lipid II accessibility
From Fig. 3 A, it can be seen that the headgroup of lipid II is
fully exposed to water and sits well above the headgroups of
the POPC lipids. From atomic force microscopy it has been
proposed that the headgroup of lipid II lies on average
1.9 nm above the surface of the membrane (41). In the simu-
lations, the conformation of the headgroup varied with time
with the distance between the C-terminus of lipid II and the
membrane surface always being in the range of 0.4–2.2 nm.
The sugar groups of lipid II (Fig. 3, A–C, green) were
always associated with the lipid headgroups.The effect of lipid II on membrane dynamics
The primary role of lipid II is to function as a carrier of
monomeric glycopeptide subunits for incorporation into
the nascent peptidoglycan. For this, lipid II must be able
to flip from one membrane leaflet to the other and diffuse
to the site of the growing bacterial wall. This occurs despite
lipid II having an extended C55 tail containing 10 isoamy-
lene units. Attachment to extended isoamylene tails is
used to enable the transport of a variety of substrates across
biological membranes in both pro- and eukaryotic cells. InBiophysical Journal 101(11) 2684–2692the simulations, it was observed that the tail of lipid II flips
spontaneously from one leaflet to the other, sometimes lying
completely within one leaflet whereas at other times span-
ning both leaflets (Fig. 3).
To investigate the effect of the presence of lipid II on the
structure and dynamics of the membrane, the deuterium
order parameters SCD for each carbon within the tail of lipid
II and within the palmitoyl (Pam) acyl chain of the
surrounding POPC molecules were calculated. The values
for the order parameters of carbons in the Pam acyl chain
of POPC in close proximity (within 0.3 nm) and those not
in close proximity (lying >3.0 nm away) to lipid II together
with values for the order parameters of carbons in the Pam
acyl chain of POPC in a pure POPC membrane are provided
in the Supporting Material (see Fig. S2 A). The jSCDj of
carbons 2–19 in the 55-carbon isoamylene tail of lipid II
are also given as in the Supporting Material (see Fig. S2
B). In all cases, the jSCDj values are <0.25, consistent
with the membrane being in a liquid-crystalline phase.
Beyond carbon 6, the jSCDj values were <0.1 for all atoms
in the tail of lipid II, suggesting that the acyl chain of lipid II
is significantly less ordered than the surrounding POPC. In
addition, whereas the jSCDj values of atoms in the Pam
acyl chain of POPC lying >3 nm away from lipid II were
identical to those in a pure POPC membrane, the jSCDj
values for POPC molecules lying within 0.3 nm of lipid II
were 0.05 lower. The presence of lipid II thus reduces the
local order in the membrane significantly.CONCLUSIONS
In this work, molecular dynamics simulations have been
used to shed light on the mechanism by which a receptor
molecule, in this case the glycopeptide antibiotic vancomy-
cin, recognizes and binds to a specific lipid embedded
within a membrane environment. In the simulations, vanco-
mycin bound itself spontaneously to the physiological
Binding of Vancomycin to Lipid II 2691target, membrane-bound lipid II. Depending on the relative
abundance of vancomycin and lipid II, stable 2:1 and 2:2
complexes were formed, demonstrating that 2:2 complexes
could, in principle, form on the surface of a cell. The inter-
action between vancomycin and the terminal tripeptide of
membrane-bound lipid II was virtually identical to that
observed experimentally for vancomycin bound to isolated
tripeptide analogs of lipid II free in solution. This suggests
that the membrane environment does not change the nature
of the interaction and verifies that, in this case, it is possible
to predict the interaction between vancomycin and lipid II
within experimental accuracy.
Of the two possible modes of interaction—1) direct
binding to lipid II, or 2) initial binding to the membrane
and the subsequent diffusion of vancomycin in the plane
of the membrane—direct binding was more likely to result
in a stable complex. The initial point of recognition was
shown to be the interaction between the N-terminus of van-
comycin and the C-terminus of lipid II. In those cases where
vancomycin did interact directly with the membrane, it did
not appear to adopt a preferred orientation. Also, once
bound, the diffusion of vancomycin within the plane of
the membrane was slow on the timescale of the simulations.
Even after a stable complex between vancomycin and
lipid II had formed, vancomycin did not adopt a preferred
orientation. There were no interactions between the sugar
moieties of lipid II and vancomycin observed, nor did resi-
dues 3 and 4 or lipid II (Lys and g-D-Glu) appear to form
specific stable interaction with vancomycin. Free energy
calculations were used to estimate the relative affinity of
vancomycin for resistant forms of lipid II in a membrane
environment. The calculations were validated by computing
the free enthalpy of binding of vancomycin to tripeptide
analogs of native and resistant forms of lipid II and showing
that these were in good agreement with experiment. Calcu-
lations of the free energy of binding of vancomycin to the
equivalent forms of lipid II embedded within a membrane
suggests that the presence of the membrane does not affect
the relative binding affinity of different terminal tripeptides
significantly.
Overall, the work has added to our understanding of the
interaction of vancomycin with membrane-bound lipid II
and demonstrated that simulations can predict the structural
and thermodynamic properties of membrane-bound
complexes with near-experimental accuracy.SUPPORTING MATERIAL
Tables summarizing the simulations performed to investigate the sponta-
neous binding of vancomycin to membrane bound lipid II and to estimate
the relative binding affinities of lipid II analogues to vancomyicin are are
available at http://www.biophysj.org/biophysj/supplemental/S0006-3495
(11)01311-7. Also provided are a schematic showing all closed thermody-
namic cycles calculated in this work together with the change of free
enthalpy for each individual mutation as well as a plot of deuterium order
parameters jSCDj of the palmitoyl (Pam) acyl chains of POPC.We thank Dr. Alpeshkumar K. Malde for assistance in the generation of the
topology for vancomycin and lipid II. We also thank Dr. Mark Blaskovich
for helpful discussions.
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